PMI: People Want Governments to Give Smokers Better Choices, Say Majority of 31,000 People Polled in 31 Countries Worldwide
A new global survey* commissioned by Philip Morris International and conducted by Ipsos reveals that 77 percent of adults agree that governments should do all they can to encourage men and women who would otherwise keep smoking cigarettes to completely switch to better alternatives.
Smoking is still ranked as an important public health issue alongside obesity, alcoholism and opioid use in terms of importance. Importantly, the multinational survey shows strong support for the role that innovation and technology should play in resolving these global health problems.
Dr. Moira Gilchrist, Vice President of Scientific and Public Communications at Philip Morris International, said: “This survey shows that most people around the world agree that smoking is still a serious public health problem. They want to see action to tap into the opportunity provided by alternatives to cigarettes that are scientifically substantiated. We are in complete agreement with that view. Public opinion aligns with common sense, and the survey confirms what we have heard for more than a decade.”
The results also showed that 86 percent of respondents believe consumer goods companies have an obligation to continually research and innovate their products in the interest of public health. However, only 35 percent thought that governments have done a good job to ensure everyone has access to the latest innovations and advancements. Clearly, society does not want governments to block promising solutions to public health problems.
Publication of the study results follows a meeting of the WHO Framework Convention on Tobacco Control (FCTC) Conference of Parties (COP) in Geneva last week, where the 181 member countries and non-governmental organizations (NGOs) met to decide on global tobacco control policy recommendations. None of their discussions were open to the public or media. Although many individual states took progressive positions, the disappointing and unfortunate outcome of the COP will mean that millions of smokers will not know about better alternatives to cigarettes. This approach is in sharp contrast with public opinion: 92 percent of those surveyed agreed that smokers should have access to accurate information to guide their choices.
“The science is clear. The evidence shows that switching to a smoke-free product is a better choice than continuing to smoke. We simply cannot keep smokers in the dark about this information. The COP missed an opportunity to put people and science at the heart of its policymaking,” added Dr. Gilchrist.
Contrary to common sense, the tobacco industry has been discouraged from innovating and inadvertently encouraged to keep cigarettes at the core of their business models. Despite this, at PMI we will not waiver from our commitment to provide the world’s 1.1 billion smokers with better alternatives to cigarettes, as well as information about these options.
Countries now have the opportunity to implement local regulations that embrace science and technology. Progressive polices can effectively protect overall population health, while still working in the best interests of men and women who smoke.
“With any other global problem, from the environment to obesity, everyone works together to deliver better alternatives, inform people about them and incentivize them to change behavior. Why should this common sense approach not apply to tobacco?” concluded Dr. Gilchrist.
The clear call from society for more information about, and access to, better alternatives to cigarettes did not come without important caveats that we support. Of those surveyed, 92 percent agreed that these new products must have robust scientific testing prior to being introduced into the market, and 91 percent agreed that once these products have been introduced their impact needs to be monitored to ensure they are reducing the harm caused by cigarettes.
* Conducted by Ipsos Hong Kong Limited (September 2018); margin of error ±0.6% at the 95 percent confidence interval. All data can be viewed at www.pmi.com/media-center/news/public-supports-alternatives-to-cigarettes
Philip Morris International: Who We Are
We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products that are a much better consumer choice than continuing to smoke cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirements. Our vision is that these products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. For more information, see our PMI and PMIScience websites.
Philip Morris International
+41 (0) 79 549 1968
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00 | Pressemelding
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.